FMR LLC & Abigail Johnson Trim Taysha Gene Therapies Stake to 12.002%
Ticker: TSHA · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1806310
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, amendment, biotech
TL;DR
**FMR LLC and Abigail Johnson still own 12.002% of Taysha, a slight trim but still a big vote of confidence.**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Taysha Gene Therapies, Inc. (TSHA) to 12.002% of the common stock, totaling 22,439,124 shares, as of February 9, 2024. This amendment, filed under Rule 13d-1(b), indicates a significant, but slightly reduced, passive investment by a large institutional holder. For investors, this means a major player still sees value in Taysha, but the slight decrease in percentage ownership could signal a minor rebalancing of their portfolio.
Why It Matters
A prominent institutional investor like FMR LLC maintaining a significant, albeit slightly reduced, stake can influence market perception and provide a degree of stability for Taysha Gene Therapies' stock.
Risk Assessment
Risk Level: low — The filing indicates a passive investment by a large, diversified institutional investor, with no immediate signs of aggressive action or significant divestment.
Analyst Insight
Investors should note that a major institutional holder like FMR LLC still has a substantial position, which could be seen as a vote of confidence, but the slight reduction in percentage ownership suggests a re-evaluation rather than a strong bullish or bearish signal.
Key Numbers
- 22,439,124 — Shares Beneficially Owned (Total common stock shares of Taysha Gene Therapies, Inc. held by FMR LLC and Abigail P. Johnson.)
- 12.002% — Percent of Class (The percentage of Taysha Gene Therapies, Inc.'s common stock owned by FMR LLC and Abigail P. Johnson.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, principal owner of FMR LLC
- Taysha Gene Therapies, Inc. (company) — issuer of the common stock
- 22,439,124 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 12.002% (dollar_amount) — percentage of class beneficially owned
Forward-Looking Statements
- FMR LLC will likely maintain a significant, passive stake in Taysha Gene Therapies, Inc. for the foreseeable future. (FMR LLC) — medium confidence, target: 2025-02-09
FAQ
Who are the primary reporting persons in this SC 13G/A filing?
The primary reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing for both entities.
What is the total number of Taysha Gene Therapies, Inc. common stock shares beneficially owned by FMR LLC and Abigail P. Johnson?
FMR LLC and Abigail P. Johnson beneficially own a total of 22,439,124 shares of Taysha Gene Therapies, Inc. common stock, as indicated in Item 4(a) for FMR LLC and Item 7 for Abigail P. Johnson.
What percentage of Taysha Gene Therapies, Inc.'s common stock does FMR LLC and Abigail P. Johnson collectively own?
FMR LLC and Abigail P. Johnson collectively own 12.002% of Taysha Gene Therapies, Inc.'s common stock, as stated in Item 11 for both reporting persons and Item 4(b) for FMR LLC.
Under which SEC rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed pursuant to Rule 13d-1(b), as indicated by the 'x' in the appropriate box on the first page of the filing.
What is the CUSIP number for Taysha Gene Therapies, Inc. common stock?
The CUSIP number for Taysha Gene Therapies, Inc. common stock is 877619106, as listed under 'Cusip #877619106' and Item 2(e).
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Taysha Gene Therapies, Inc. (TSHA).